zalifrelimab (UGN-301) / Agenus, UroGen 
Welcome,         Profile    Billing    Logout  
 0 Diseases   8 Trials   8 Trials   121 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
zalifrelimab (UGN-301) / Agenus, UroGen
NCT04430036: AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer

Terminated
2
4
US
AGEN1884, anti-CTLA-4 antibody, AGEN2034, Anti-PD-1, Cisplatin, Gemzar, Platinol® and Platinol®-AQ, Gemcitabine, Gebina, Gemalata, Gembin, Gembine, Gembio, Gemcel, Gemcetin
The University of Texas Health Science Center at San Antonio
Urinary Bladder Neoplasms
10/21
03/22
NCT04028063: Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting
2
28
US
Balstilimab, AGEN2034, Zalifrelimab, AGEN1884, Doxorubicin, Lipodox, Doxil, Botensilimab, AGEN1181
University of Colorado, Denver, Agenus Inc.
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
11/25
11/26
RAPIDS, NCT03894215: RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer

Active, not recruiting
2
212
US, RoW
AGEN2034, AGEN1884
Agenus Inc., GOG Foundation
Cervical Cancer
01/25
09/26
NCT05033132: A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer

Withdrawn
2
177
RoW
Balstilimab, Balstilimab + Zalifrelimab
Agenus Inc., Betta Pharmaceuticals Co., Ltd.
Cervical Cancer
12/24
12/24
NUMANTIA, NCT04827953: Study to Evaluate the Safety and Efficacy of Treatment With NLM-001 and Standard Chemotherapy Plus Zalifrelimab in Patients With Advanced Pancreatic Cancer

Active, not recruiting
1/2
28
Europe
Gemcitabine, Nab paclitaxel, NLM-001, Zalifrelimab
Nelum Corp, Apices Soluciones S.L., Agenus Inc.
Pancreatic Ductal Adenocarcinoma
04/25
04/25
NCT04943848: rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Recruiting
1
36
US
rHSC-DIPGVax, vaccine, Balstilimab, checkpoint blockade, anti-PD1, Zalifrelimab, anti-CTLA4
Ann & Robert H Lurie Children's Hospital of Chicago, Dana-Farber Cancer Institute, Children's Hospital of Orange County, University of Calgary
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
06/25
12/25
NCT05375903: A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Active, not recruiting
1
51
Europe, US
UGN-301, UGN-301 (zalifrelimab) intravesical solution, UGN-201, UGN-201 (imiquimod) intravesical solution, Gemcitabine
UroGen Pharma Ltd.
Non-muscle Invasive Bladder Cancer, NMIBC, Carcinoma in Situ of Bladder, Bladder Cancer, Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
12/25
12/25
NCT05572970: Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Available
N/A
NA
Balstilimab, AGEN2034, Zalifrelimab, AGEN1884
Agenus Inc.
Cancer
 
 

Download Options